105 – Tofacitinib dosing for ulcerative colitis, Sarepta’s second Duchenne drug; House to vote on 'right to try' drug bill
Archived series ("Inactive feed" status)
When? This feed was archived on October 07, 2018 00:40 (). Last successful fetch was on August 31, 2018 22:03 ()
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 200601714 series 1587676
March 13, 2018
Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com
1:04 FDA panel backs proposed tofacitinib dosing for ulcerative colitis https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_favorable_outcome_of_fda_advisory_committee_meeting_on_xeljanz_tofacitinib_for_moderately_to_severely_active_ulcerative_colitis
2:24 Sarepta to seek FDA approval this year for second Duchenne drug https://www.bizjournals.com/boston/news/2018/03/12/sarepta-to-seek-fda-approval-this-year-for-second.html
4:00 House to vote Tuesday on 'right to try' drug bill http://thehill.com/policy/healthcare/377863-house-to-vote-tuesday-on-right-to-try-drug-bill
Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com.
Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
100 episodes